medigraphic.com
ISSN 1817-5996 (Electronic)

2015, Number 2

<< Back Next >>

Rev Cub de Reu 2015; 17 (2)

Specific antinuclear antibodies and clinical features in 180 patients with systemic lupus erythematosus

Kokuina E, Estévez TM, Gutiérrez Á, Ortiz A, Sánchez Y, Pérez CD

Language: Spanish
References: 31
Page: 104-111
PDF size: 518.86 Kb.


ABSTRACT

Objective: to determine the prevalence of the most frequent antinuclear antibody reactivity’s and their associations with clinical features in Cuban patients with systemic lupus erythematosus.
Methods: clinical data present during the last year were obtained from 180 consecutive patients with systemic erythematous lupus. Serum samples were screened for seven autoantibodies (anti–double stranded DNA, anti-nucleosome, anti-Sm, anti-RNP, anti-Ro, anti-La, and anti-topoisomerase 1 by ELISA. To determine associations between autoantibodies and clinical features, x2 or Fisher’s exact tests were used.
Results: the Anti-Nuc antibodies were the most frequent in systemic erythematous lupus patients (75.0 %). The anti-Nuc antibodies were strongly associated with neurological (p ‹ 0.001) and joint involvement (p ‹ 0.001), the anti-dsDNA with cytopenia, and the anti-Sm and anti-RNP with neurological involvement (p ‹ 0.001). The most associated marker with renal involvement was low serum C4 (p ‹ 0.001). Cytopenia was associated with several distinct autoantibody specificities (anti-Nuc, anti-dsDNA, anti-Sm, anti-RNP and anti-Topo 1), while no association was detected between mucocutaneous lesions and the presence of serological markers.
Conclusion: anti-Nuc, anti-dsDNA, anti-Smand anti-RNP antibodies were strongly associated with several clinical features in systemic lupus erythematosus patients. These findings offer meaningful information to improve the clinical management of Cuban patients with systemic erythematous lupus.


REFERENCES

  1. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev. 2012;11:593-5.

  2. Tan EM, Cohen AS, Fries JF, Masi AT, Mc Shane DJ, Rithfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.

  3. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86.

  4. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1129-37.

  5. Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I, Borghi MO. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol. 2014;10:35-43.

  6. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000;43:76-84.

  7. Cervera R, Viñas O, Ramos-Casals M, Font J, Garcia-Carrasco M, Siso A, et al. Antichromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann RheumDis. 2003;62:431-4.

  8. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Antinucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology. 2004;43:220-4.

  9. Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol. 2007;36:291-8.

  10. Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol. 2007;122:115-20.

  11. Tikly M, Gould T, Wadee AA, van der Westhuizen E, Mokgethwa BB. Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus. Clin Rheumatol. 2007;26:2121-5.

  12. Pradhan VD, Patwardhan MM, Ghosh K. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies. Indian J Dermatol Venereol Leprol. 2010;76:145-9.

  13. Abdel Gawad ER, Mansour AI, AbdelAziz YA, Soliman AF, Fawzy RM. Role of anti-nucleosome antibodies in the diagnosis of systemic lupus erythematosus and as a marker for lupus nephropathy. Egypt J Immunol. 2014;21:57-65.

  14. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev. 2012;12:97-106.

  15. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011;13:R38.

  16. Pisetsky DS. Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol. 2012;76:223-8.

  17. Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P. Anti-nucleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity. 2009;42:393-8.

  18. Shabana AA, El-Ghawet AE, Machaly SA, Abu Hashim EM, El-Kady BA, Shaat R. Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus. Clin Rheumatol. 2009;28:673-8.

  19. Andrejevic S, Jeremy I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci-Nikolic B. Immunoserological parameters in SLE: high-avidity anti-ds DNA detected by ELISA are the most closely associated with the disease activity Clin Rheumatol. 2013,32:1619-26.

  20. O’Flynn J, Flierman R, van der Pol P, Rops A, Satchell SC, Mathieson PW et al. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol. 2011;49:75-83.

  21. Kim H-A, Jeon J-Y, Choi G-S, Sung J-M, Kim M-J, Yun J-M, et al. The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol. 2008;128:277-83.

  22. Lu R, Robertson JM, Bruner BF, Guthridge JM, Neas BR, Nath SK, et al. Multiple Autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort. Autoimmune Diseases; 2012: Article ID 819634, 11 pages, doi:10.1155/2012/819634

  23. Vilá LM, Molina MJ, Mayor AM, Peredo RA, Santaella ML, Vilá S. Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus. Lupus. 2006;15:892-8.

  24. De Giorgio LA, Konstantinov KN, Lee SC, Hardin JA, Voipe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 200;11:1189-93.

  25. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology. 2004;43:1555-60.

  26. Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis. 2003;62:556-60.

  27. Villalta D, Romelli PB, Savina C, Bizzaro N, Tozzoli R, Tonutti E, et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus. 2003;12:31-6.

  28. Hoffman IEA, Peene I, Meheus L, Huizinga TWJ, Cebecauer L, Isenberg D et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann RheumDis. 2004;63:1155-8.

  29. Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality? Autoimmunity Reviews. 2010;9:756-60.

  30. Gussin HA, Ignat GP, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:376-83.

  31. Vilá LM, Mayor AM, Valentín AH, Rodríguez SI, Reyes ML, Acosta E, et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R HealthSci J. 1999;18:89-94.




2020     |     www.medigraphic.com